Although currently available drugs to treat asthma are effective in most patients, a proportion of patients do not respond or experience side-effects; which is partly genetically determined. Pharmacogenetics is the study of how genetic variations influence drug response. In this review, we summarize prior results and recent studies in pharmacogenetics to determine if we can use genetic profiles for personalized treatment of asthma.
INTRODUCTION
Asthma is a chronic inflammatory airway disease that affects more than 300 million people worldwide. It is a heterogeneous disease, with considerable variation in age at onset, clinical expression, and severity, which may reflect heterogeneity in causal pathways. Therefore, asthma is considered by some authors to be a syndrome rather than one disease [1 & ]. The three main classes of drugs currently prescribed to patients with asthma are b2-agonists, both short-acting b2-agonist (SABA) and long-acting b2-agonist (LABA), inhaled corticosteroids (ICSs), and leukotriene modifiers (LTMs). In addition, in the past years biologicals, such as antiIgE, soluble IL-4 receptor, anti-thymic stromal lymphopoietin (TSLP), anti-IL-5, and anti-IL-13 have been investigated in patients with severe asthma, specifically targeting cytokines relevant to specific causal pathways in asthma [1 & ]. The response to asthma treatment is heterogeneous; and there is great interindividual variation in response to asthma drugs. This variation in treatment response is partly genetically determined. The discovery of genes important in asthma development and treatment response now opens up the opportunity to tailor asthma treatment to the right patient, and make it more personal.
Current international treatment guidelines mostly use a 'one size fits all' approach, where choice of asthma drugs is based on a stepwise treatment protocol for all patients [2] . This protocol is very similar for any subtype of asthma: childhood and adult onset, allergic and nonallergic, or occupational asthma. This results in a trial and error approach to find an effective treatment strategy for the individual patient. Can we do better?
Personalized or precision medicine is the tailoring of healthcare to the individual through the identification of clinical markers, biomarkers, or genetic features. We prefer to use the term precision medicine, as we expect that evidence on treatment efficacy will mostly depend on groups of patients rather than individual patients. In 2015, the Precision Medicine Initiative was launched in the United States, boosted by the availability of largescale databases (such as the human genome sequence), powerful methods for characterizing patients (such as proteomics, metabolomics, and genomics), as well as computational tools for analyzing large sets of data [3 && ]. Whereas any genetic, gene expression, or biomarker can be used to make asthma treatment more precise (Table 1) , much attention has been given to the role of genetic variation in asthma treatment (pharmacogenetics).
Pharmacogenetics, the study of how inherited genetic variations influence drug response, will be the main topic of this review. All genes harbor variants, most of which are single-DNA base pair substitutions, called single-nucleotide polymorphisms (SNPs). Two different study designs can be used. In a candidate gene study, genes are selected that are potentially relevant to the pharmacokinetic or pharmacodynamic properties of a drug. In a genome-wide association study (GWAS), the whole genome is investigated by genotyping hundreds of thousands of SNPs that cover most of the genetic variation to identify novel gene variants that influence therapeutic responsiveness.
In this review, we summarize prior results, highlight important studies over the past 18 months in asthma pharmacogenetics and explore future directions. The methods used for this review are outlined in Table 2 .
b2-AGONISTS
Inhaled b2-agonists are widely used bronchodilators that are available in three classes: SABA, LABA, and ultra-long acting b2-agonist. b2-agonists bind to the b2-adrenoreceptor (b2AR), a G protein-coupled receptor present mainly on airway smooth muscle cells. Stimulation of the b2AR induces a signal transduction pathway, resulting in increased intracellular cyclic-3 0 ,5 0 -adenosine monophosphate and activation of protein kinase A. Cyclic-3 0 ,5 0 -adenosine monophosphate increases intracellular calcium retention and protein kinase A phosphorylates key regulatory proteins; both resulting in airway smooth muscle relaxation.
Pharmacogenetic studies of b2-agonists have mainly focused on the gene encoding the b2AR (ADRB2). The most extensively studied SNP in the ADRB2 gene is glycine for arginine at codon 16 (rs1042713), which is present in its homozygous form in about 16% of the Caucasian population, and has been related to enhanced receptor downregulation in vitro. The homozygous Arg16 variant has been associated with a decline in lung function and increase in exacerbations after regular SABA therapy in adolescent and adult asthmatic patients. One of the very first prospective pharmacogenetic trials in medicine was performed in asthmatic adults stratified on rs1042713 genotype [4] . This Beta Adrenergic Response by Genotype (BARGE) trial investigated the response to 16-weeks regular albuterol (salbutamol) four times per day compared with placebo. Arg16 homozygotes had lower morning peak flow and demonstrated a deterioration of symptom control during albuterol treatment, in contrast to Gly16 homozygotes. This finding is consistent with the in-vitro observations indicating that continuous stimulation of the b2AR would lead to enhanced receptor downregulation in Arg16 homozygotes, with relative protection against downregulation in Gly16 homozygotes. However, the clinical relevance of this finding is limited, as current guidelines advice to use albuterol as needed, and not on a regular basis.
Studies searching for the effect of rs1042713 on the response to treatment with LABAs have shown conflicting results, and the adverse effects appear less evident in adults than in children [5, 6 && ,7,8
KEY POINTS
Precision medicine is the tailoring of healthcare to the individual through the identification of clinical, biological, or genetic markers.
Evidence on the adverse effects of LABAs in children homozygous for the Arg16 allele of the rs1042713 polymorphism is increasing.
Although a growing number of genetic loci have been associated with therapeutic responses to glucocorticoids, the individual effect of each SNP is limited.
The first GWASs on treatment response to LTM have identified novel genetic loci associated with lung function response to LTM.
Future studies should use a polygenic predictive approach integrated in complex networks of multiple 'omics'.
In asthmatic adults, the prospective, genotypestratified, crossover Long-acting b2-Adrenergic Response by Genotype (LARGE) trial investigated the response to 18-week twice daily add-on salmeterol compared with placebo [5] . Lung function improved in both Arg16 and Gly16 homozygotes during LABA treatment, but only Gly16 homozygotes were protected against bronchial hyperresponsiveness provoked by metacholine [5] . In a recent publication, Wechsler et al. [6 && ] reported no negative associations between the rs1042713 polymorphism and the effects of 18-week add-on LABA compared with tiotropium on time to asthma exacerbation, quality of life, Asthma Control Questionnaire score, and forced expiratory volume in 1 s (FEV 1 ) in 1070 black asthmatic adults using ICSs.
In children, an increased risk for exacerbations was found in Arg16 homozygotes in a cohort of 1182 patients (aged 3-22 years) on daily salmeterol [7] . Recently, data from 4226 children from five independent populations of white Northern European and Latino origin were meta-analyzed, showing an increased odds ratio (OR) for asthma exacerbations of 1.52 (P ¼ 0.0021) for each copy of the Arg16 allele among children treated with ICSs plus LABA [8 && ]. Lipworth et al. [9] showed in a prospective randomized trial that in patients aged 5-18 years with the Arg16 homozygous genotype on ICSs add-on montelukast compared with salmeterol significantly improved asthma symptoms, asthma-related school absence, and quality of life. Thus, in contrast to the adult data, evidence on the adverse effects of LABAs in children carrying the Arg16 allele is increasing, and future studies should address if prospective genotyping of this SNP could improve medication advices to children not controlled on ICSs.
Several GWASs on bronchodilator response to SABAs have been performed, identifying SNPs associated with increased bronchodilator response to albuterol, such as rs295137 in the promotor region of SPATS2L (a gene affecting b2AR expression) [10] , and polymorphisms in SPATA13-AS1 (a gene involved in smooth muscle contraction) [11] . Although some of these findings were replicated in independent cohorts, none met the threshold of genome-wide significance. Recently, Israel et al. [12 & ] published the results of a GWAS in which they studied 444 088 SNPs in 724 white adults and children with mild-to-moderate asthma. They identified four SNPs that were associated with decreased FEV 1 response to albuterol. These findings were replicated in an independent cohort of 439 adults with moderate-tosevere asthma. The combined P value for these SNPs reached statistical genome-wide significance in a meta-analysis of the discovery and replication cohorts together. All four SNPs map to a genetic region on chromosome 2 near ASB3, a gene associated with smooth muscle proliferation. We searched MEDLINE, Web of Science, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL) and Clinicaltrials.gov to identify English language articles published between January 2015 and July 2016. We used the search terms 'asthma' in combination with 'pharmacogenetics' or 'pharmacogenomics' or 'personalized medicine', 'precision medicine' or 'individualized medicine'. Reference types were randomized controlled trials, reviews, and editorials. The articles were reviewed by the authors and those deemed most relevant were used in this review. We also searched the reference lists of articles identified by our search strategy and selected those we judged relevant. Additionally, we selected some references based on our previous knowledge of the subject. No exclusion criteria were used. In reporting the published evidence, priority was given to recent studies, genetic findings that were genome wide significant and/or replicated, or studies with a high-quality study design, such as prospective randomized controlled studies.
Many other candidate genes have been associated with an increased or decreased bronchodilator response to SABAs, as reviewed by Blake and Lima in 2015 [13 & ], and summarized in Table 3 . These studies suggest that variants in the b2-agonist signaling pathway [14, 20, 23] and variants in the nitric oxide (an endogenous bronchodilator) biosynthetic pathway [16] [17] [18] can influence the acute bronchodilator response to SABAs, but few have studied the effect on treatment response to LABAs. Future prospective genotype-stratified studies are necessary to confirm these associations and study the effect on LABA responsiveness.
GLUCOCORTICOIDS
ICSs are the most potent and commonly used firstline anti-inflammatory agents in the treatment of asthma. Glucocorticoids bind to glucocorticoid receptors in the cytoplasm and are then translocated into the nucleus. There, the activated glucocorticoid receptors bind to glucocorticoid response elements in glucocorticoid-responsive genes either encoding anti-inflammatory proteins or repressing proinflammatory proteins.
Many pharmacogenetic studies of glucocorticoids focus on candidate genes encoding proteins involved in the glucocorticoid pathway, such as corticotropin-releasing hormone receptor 1 (encoded by CRHR1), proteins that form the glucocorticoid receptor heterocomplex and factors responsible for the assembly of this heterocomplex. Hawkins et al. [25] identified four SNPs in the STIP1 gene encoding heat-shock organizing protein that correlated with improvement in lung function after 4 and 8 weeks of ICS treatment in white asthmatic adults. Vijverberg et al. [26 & ] reported that the ST13 SNPs rs138335 and rs138337 were associated with an increased risk of asthma-related hospital visits in northern European children and adolescents on ICSs. ST13 encodes a cochaperone protein (Hsp70 interacting protein) of the glucocorticoid receptor heterocomplex. Alterations in the expression or folding of cochaperones like heat-shock organizing protein and Hsp70 interacting protein may alter binding of glucocorticoids to the receptor and thereby influence ICS responsiveness.
In a small prospective study, Keskin et al.
[27 & ] were the first to evaluate the pharmacogenetics of the acute response to a single high dose of ICS during an asthma exacerbation. They studied the effect of eight SNPs that were previously identified to influence the long-term response to ICS, and found only one (rs41423247 in the NR3C1 gene encoding the glucocorticoid receptor) to be associated with a higher acute improvement in FEV 1 . This study suggests that the genetic variants that influence the variability in response to maintenance treatment may differ from those underlying acute treatment responses.
New candidate genes that might influence the response to ICSs were identified through GWAS. Tantisira et al. [28] identified a SNP (rs37972) in the promoter region of the glucocorticoid-induced transcript 1 gene (GLCCI1) that was associated with an impaired lung function response to ICS treatment in four independent populations comprising 935 white adults and children. This SNP was in complete linkage disequilibrium with rs37973, a functional SNP that downregulates GLCCI1 expression and could cause a decreased response to exogeneous glucocorticoids. However, two subsequent studies in non-Hispanic white adults [29] , and in northern European white children and adolescents [30] , were unable to find an association of this variant with FEV 1 response, risk of exacerbations, or uncontrolled symptoms.
Dahlin et al. [31 & ] found a novel SNP, rs2395627, in the CMTR1 gene, associated with an increased risk of asthma exacerbations despite ICS treatment in a GWAS study conducted in 806 Caucasian asthmatic adults and children. CMTR1 encodes a methyltransferase that catalyzes methylation of RNA transcripts and participates in the cellular defense against viral infections. They hypothesized that this gene may play a role in the pathogenesis of asthma exacerbations because of viral infections despite ICS treatment and reported upregulated CMTR1 mRNA expression in nasal lavage samples from 18 asthmatic children during acute exacerbations, compared with 1-2 weeks following an exacerbation.
Wang et al. [32 && ] described a novel approach to GWAS by using a pharmacodynamic model to study dose-response relationships based on repeated measures of drug response at multiple dosages. They identified five SNPs with significant effects on response curves of corticosteroids for asthma. Four of these SNPs were associated with lung function response to ICSs in a replication in three independent clinical trials. These SNPs were located in the vicinity of candidate genes associated with oxidized nicotinamide adenine dinucleotide (NADþ) metabolism (such as TNKS), oxidative damage repair (such as MSRA), and genes related to nicotine dependence (such as MYO1E).
In the past decade, several other genes have been associated with either increased or decreased responsiveness to maintenance treatment with ICSs, as summarized in Table 4 . However, many of these findings have not been replicated. This could be because of the use of different endpoints, heterogeneity in study groups (based on ethnicity, age, sex, and asthma phenotype) and in treatment regimens. Furthermore, the response to glucocorticoids involves numerous proteins, therefore, the individual effect of one SNP is very limited and it is not possible to predict the clinical response to ICSs based on these SNPs. For future studies of drug response to ICSs a polygenic approach would be more appropriate, preferably integrated in complex networks using systems biology and multiple omics. For example, SNPs could be integrated with epigenetic changes and gene expression patterns that predict treatment response, thereby improving prediction.
LEUKOTRIENE MODIFIERS
LTMs block the actions of cysteinyl leukotrienes (CysLT); a group of lipid mediators derived from arachnidonic acid by the enzyme 5-lipoxygenase (5-LO). CysLT promote bronchoconstriction, plasma exudation, and mucus secretion, mainly through their effect on the CysLT receptor 1. LTMs exert their effect either by inhibiting 5-LO or antagonizing the CysLT receptor 1.
Pharmacogenetic studies of LTMs have mainly focused on candidate genes encoding enzymes involved in the synthesis and transport of CysLT and the CysLT receptors. In the first pharmacogenetic study looking at LTM responsiveness, Drazen et al. [45] reported a decreased FEV 1 response to 2-week treatment with 5-LO inhibitor ABT-761 in patients with a tandem repeat polymorphism in the promotor region of the ALOX5 gene coding for 5-LO. However, the allele frequency of the ALOX5 repeat polymorphism is too low (less than 2% in Caucasians) to fully explain the variability in response to LTM. Early studies indicated a NOS3 rs1799983 n/r increased FEV 1 response to LABA/ICS combination [24] FEV 1 , forced expiratory volume in 1 s; ICS; inhaled corticosteroid; LABA; long-acting b2-agonist, SABA; short-acting b2-agonist, n/r; not reported. a As reported in cited reference; in case allele frequency was specified in different ethnic populations, the allele frequency in Caucasians is reported.
polymorphism in LTC4S, encoding leukotriene C4 synthase that converts LTRA4 to LTRC4, is associated with an increased FEV 1 response to LTM [46] . Subsequent larger studies confirmed the influence of the ALOX5 promotor variant and the protective effect of LTC4S SNP rs730012 [47] , on exacerbation rates during treatment with montelukast. Further studies identified additional SNPs associated with FEV 1 response to montelukast in the ALOX5 gene [47] [48] [49] , in MRP1 (a gene coding for a transmembrane protein that transports LTC4 to the extracellular space) [47, 49] , and in CYSLTR2 [48] , as summarized in Table 5 . However, most of these results have not been replicated. Recently, Dahlin et al. [50 && ] published the results of the first GWAS on the response to LTM. First, they performed a GWAS of the FEV 1 response to 12-week treatment with zileuton in a cohort of 304 adult asthmatics. Then, they tested the replicability of the top 50 SNPs in a cohort of 222 asthmatics aged ! 12 years treated with zileuton for 12 weeks. In the combined analysis, one SNP (rs12436663) in MRPP3, a gene that encodes a mitochondrial RNase P protein, reached genome-wide significance. Homozygous carriers of the minor allele had a significantly worse FEV 1 response to treatment. MRPP3 has previously been linked to cardiovascular and autoimmune diseases, and variations within its coding region may affect leukotriene synthesis or processing, but its exact role remains to be unraveled. The authors then tested the replicability in two independent cohorts of asthmatic patients receiving 12 weeks of treatment with montelukast. This analysis identified one SNP (rs517020), in the intron of the gene glycosyltransferase 1 domain containing 1 (GLT1D1), associated with reduced responses to both zileuton and montelukast. This suggests that some genes may have a class effect on all LTM, whereas others may only influence the response to either 5-LO inhibitors or leukotriene receptor antagonists. In a second GWAS, the same study group performed a GWAS of the FEV 1 response to 8-week treatment with montelukast in two cohorts comprising 133 adult asthmatics [51 & ]. Then, they tested the replicability of the top 200 SNPs in two independent cohorts comprising 184 asthmatics aged ! 6 years. Four SNPs were replicated in all four cohorts, of which one variant, rs6475448, achieved genomewide significance. Homozygous carriers of this SNP showed an increased FEV 1 response to montelukast. rs6475448 is present within MLLT3, a gene proposed to regulate cell fates for megakaryocytes and erythroid cells. Red blood cell precursors are capable of transforming arachidonate and LTA4 to bioactive eicosanoids, and could play a role in the leukotriene pathway. Additional studies, including prospective genotype stratified studies, are necessary to confirm the association of MRPP3, GLT1D1, and MLLT3 with LTM responses.
NOVEL THERAPIES
In the past years, novel biologic therapies, such as anti-IgE, soluble IL-4 receptor, anti-TSLP, anti-IL-5, and anti-IL-13 have been investigated in patients with severe asthma, specifically targeting cytokines of biologic pathways in asthma. Pharmacogenetic biomarkers could aid to identify subgroups of patients responsive to these drugs. For example, in a dose ranging study of pitrakinra, an IL-4/IL-13 pathway antagonist that blocks the IL-4a receptor subunit encoded by IL4RA, the frequency of exacerbations was significantly reduced in study participants with a specific IL4RA variant; the GG genotype in the SNP rs8832 [52] . Other candidate genes that might influence response to novel biologicals are those encoding Th2-cytokines and their receptor, such as a variant of the IL-13 gene that was recently associated with increased FEV 1 response to 2 years of ICS treatment [53] .
CONCLUSION
In the past years, there has been much progress in the field of pharmacogenetics both by candidate gene studies and GWAS. New technologies, such as admixture mapping, the use of expression Quantitative trait loci and RNAseq are used to enrich GWAS results. An expanding number of genetic loci have been associated with therapeutic responses. ] have calculated that pharmacogenomics testing to predict response to ICSs is potentially cost-saving and noninferior in improving health. However, we are still far away from applicability in clinical practice.
The only polymorphism that has currently been studied in prospective, genotype stratified treatment studies has been the glycine for arginine substitution at codon 16 in the ADRB2 gene (rs1042713), with conflicting outcomes for SABAs and LABAs in adults [4,5,6 && ]. However, evidence on the adverse effects of LABAs in children homozygous for Arg16 allele is increasing [8 && ]. Future studies should address if prospective genotyping of this SNP could improve medication advices to children not controlled on ICSs.
For other asthma drugs, especially ICSs, we are further away from clinical practice. Researchers have struggled to replicate many of the previously described associations, which could be because of underpowered sample sizes, heterogeneous populations, different asthma phenotypes or treatment regimens, and different endpoints used to assess treatment response. As numerous different proteins are involved in the treatment response to medications, the individual effect of one SNP is limited. Furthermore, epigenetic changes (such as DNA methylation, histone modification, and RNAassociated silencing), gene-gene interactions, and gene-environment interactions (including interactions of drug combinations) could all affect pharmacogenetic associations. To achieve personalized treatment, we need a polygenetic approach, in which a panel of variants predictive of therapeutic responsiveness is used, preferably integrated in complex networks of multiple omics.
